With declining COVID-19 product revenue, Pfizer is successfully shifting its focus to its core business. The non-COVID portfolio demonstrated robust 9% operational growth in Q4, underscoring the strength of its underlying commercial assets and recent launches.
Pfizer is making a concentrated push into oncology and obesity, two of the largest potential future markets. The integration of Sigen's ADC technology and the rapid development of the Metzera obesity portfolio are positioned as primary growth drivers for the latter half of the decade.
The company emphasized a productive year for R&D, with numerous approvals, data readouts, and pivotal study initiations. Key upcoming catalysts include readouts for Albrexio in multiple myeloma and a novel ADC for lung cancer, demonstrating a commitment to converting scientific innovation into commercial products.
While investing heavily in R&D ($10.4B) and business development ($8.8B), Pfizer is simultaneously executing a large-scale productivity program to achieve $7.2 billion in net cost savings. This is coupled with a strong commitment to shareholder returns, evidenced by a significant dividend payout.
Pfizer is scaling its artificial intelligence capabilities, planning to expand its compute power to over 1,200 GPUs. AI is being embedded across R&D, manufacturing, and commercial operations to accelerate drug development timelines, optimize supply chains, and personalize marketing.
Keep pulling the thread on Yaw Pharma.